Bio-gene Technology Ltd. · ASX:BGT
Bio-gene Technology — Shareholder Meeting (November 2019)
12 slides from Bio-gene Technology's shareholder meeting presentation, Nov 26, 2019
Slide 1: 2019 AGM CEO Update
ASX: BGT 2019 AGM CEO Update Richard Jagger 26 November 2019
Slide 2: Disclaimer
2 Disclaimer This presentation has been prepared by Bio-Gene Technology Limited (ASX:BGT) (the Company). This presentation is not, and should not be considered, an offer or invitation to apply for or purchase securities in the Company or as a recommendation or inducement to make an offer or invitati
Slide 3: Investment Highlights
3 Investment Highlights Bio-Gene has a compelling value proposition Data shows Low toxicity to >5,000x less Novel Mode Bio-Gene’s technology compounds are beneficial insects impactful on bee of Action addresses the needs of highly effective populations a large and growing global problem of pest resi
Slide 4: 2019 Year in Review
4 2019 Year in Review Additional safety trials • Completed study on beneficial insects showing no adverse effects • Identified & engaged a consultant to review toxicology profile and studies Anopheles Mosquito studies • Purdue University reviewing Flavocide and Qcide on malaria-carrying mosquito Sig
Slide 5: Qcide-specific progress in FY19
Qcide-specific 5 progress in FY19 Qcide progress • Significant increase in investment in Qcide programs (~47% budget) • James Cook University collaboration focusing on improved oil extraction, tree cloning program to improve yield consistency • Additional harvesting programs to test extraction techn
Slide 6: Flavocide-specific progress in FY19
6 Flavocide- specific Flavocide progress progress in Improved manufacturing FY19 • Completed CSIRO synthesis development, resulting in reduced costs, and waste, and increased yield • Scale-up program with Boron Molecular, aimed at improving on CSIRO methodology through larger production quantities •
Slide 7: Flavocide Testing
7 Flavocide Testing Prof. Catherine Hill Purdue University BGT Scientific Advisory Board Member • Purdue university, department of entomology • Showalter faculty scholar • President’s fellow for the life sciences CLICK HERE TO PLAY MOSQUITO • Authority in new TESTING VIDEO insecticide development &
Slide 8: Bio-Gene has four major target verticals
8 Bio-Gene has four major target verticals Crop Protection Grain Storage Focus remains on providing new solutions across four key target verticals Public Health Consumer Products Total Addressable market of US$25.1bn
Slide 9: Australian stored grain pest control partnership trial
9 Australian stored Contribution About grain pest control partnership trial Funding, market BASF world’s largest chemical company and access & regulatory leading developer of new chemistry to the expertise agriculture sector Department of Agriculture & Fisheries, Research Queensland Government (DAF)
Slide 10: There exists a pipeline of further potential partnerships
10 There exists a pipeline of further potential Bio-Gene aims to develop further significant partnerships from existing and future MTA’s partnerships Currently six ‘Material Transfer Agreements’ signed to explore opportunities across four key verticals globally Crop Protection Grain Storage Public H
Slide 11: Looking ahead
11 Looking ahead Advance MTA’s to partnership stage • Progress additional companies / organisations to formal agreements • Sign new MTA’s with additional companies Progressing trial data relating to vector control to enable Bio-Gene to leverage conversations with key stakeholders • Bio-Gene has iden
Slide 12: Richard Jagger CEO
Richard Jagger CEO (03) 9068 1062 richardj@bio-gene.com.au Roger McPherson CFO, Co. Sec. (03) 9068 1062 rogerm@bio-gene.com.au
Bio-Gene Technology — Shareholder Meeting (November 2019) on 6ix